神經分泌生物科學 NBIX 深 滬
已收盤 10-24 16:00:00 美东时间
144.00
+0.330
+0.23%
華盛通- 最 高144.42
- 今 開143.60
- 成交量 63.61万股
- 最 低 142.20
- 昨 收 143.67
- 總市值 142.82亿
- 52周最高 154.61
- 市盈率 靜 43.75
- 換手率 0.64%
- 52周最低 84.23
- 委 比 53.85%
- 總股本 9918.15万
- 歷史最高 157.9799
- 量 比 0.93
- 振 幅 1.55%
- 歷史最低 5.42
- 每 手 1
- 風險率 13.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews
In the last three months, 12 analysts have published ratings on Neurocrine Bios...
10-21 03:33
Neurocrine Biosciences Announced The Presentation Of New Analysis From Phase 3, Open-Label Kinect 4 Study, Which Showed Clinically Meaningful Improvement In Tardive Dyskinesia Symptoms With Once-Daily Dose Of 40 Mg INGREZZA Capsules For 48 Weeks
Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms90% of participants who completed 48 weeks of continuous treatment with
10-17 20:37
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $195
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $188 to $195.
10-10 01:35
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
<p>NanoBiotix reported operational and financial updates for the first half of 2025. Key highlights include progress in clinical trials for JNJ-1900 (NBTXR3), reclassification from a medical device to a drug, and a new patent filing. Financially, revenue increased to €26.6 million, R&D expenses decreased, and net loss narrowed to €5.4 million. Despite cash reserves of €28.8 million, the company faces liquidity challenges and is exploring non-dilu...
09-30 20:15
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Where Neurocrine Biosciences Stands With Analysts
14 analysts have shared their evaluations of Neurocrine Biosciences (NASDAQ:NBI...
09-22 20:02
